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often face limited access to orphan drugs. Managed access programmes (MAPs) are a mechanism for
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expressed support for these programmes and see patient input as critical to successful implementation.
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collaborated with patients and caregivers using the principles of participatory action research. Data were
collected at two workshops and analysed using a thematic network approach. Results: Patients and caregivers
co-designed a checklist comprised of six aspects of an ideal MAP relating to accountability (programme
goals); governance (MAP-specific committee oversight, patient input, international collaboration); and
evidence collection (outcome measures and continuation criteria, on-going monitoring and registries). They
recognized that health-care resources are finite and considered disease or drug eligibility criteria for deciding
when to use a MAP (eg drugs treating diseases for which there are no other legitimate alternatives).
Conclusions: A patient and caregiver-designed checklist was created, which emphasized patient involvement
and transparency. Further research is needed to examine the feasibility of this checklist and roles for other
stakeholders.
Disciplines

Education | Social and Behavioral Sciences
Publication Details

Young, A., Menon, D., Street, J., Al-Hertani, W. & Stafinski, T. (2018). A checklist for managed access
programmes for reimbursement co-designed by Canadian patients and caregivers. Health Expectations, 21
(6), 973-980.

This journal article is available at Research Online: https://ro.uow.edu.au/sspapers/4110

Accepted: 8 March 2018
DOI: 10.1111/hex.12690

ORIG INAL RESE ARCH PAPER

A checklist for managed access programmes for reimbursement
co-designed by Canadian patients and caregivers
Andrea Young BSc, MSc, Research Associate1

| Devidas Menon PhD, MHSA, Professor1 |

Jackie Street BSc, PhD, Grad. Dip. PHC, Senior Lecturer2 | Walla Al-Hertani MD, MSc,
FRCPC, FCCMG, Clinical Assistant Professor3 | Tania Stafinski MSc, PhD, Director1
1
Health Technology & Policy Unit, School
of Public Health, University of Alberta,
Edmonton, AB, Canada
2

School of Public Health, The University of
Adelaide, Adelaide, SA, Australia

3

Cumming School of Medicine, University of
Calgary, Calgary, AB, Canada
Correspondence
Andrea Young, Health Technology & Policy
Unit, School of Public Health, University of
Alberta, Edmonton, AB, Canada.
Email: aldunn@ualberta.ca
Funding information
This study was supported by funding from
the Canadian Institutes of Health Research
Emerging Team Grant (TR3 119194).

Abstract
Introduction: Reimbursement decisions on orphan drugs carry significant uncertainty, and as the amount increases, so does the risk of making a wrong decision,
where harms outweigh benefits. Consequently, patients often face limited access to
orphan drugs. Managed access programmes (MAPs) are a mechanism for managing
risk while enabling access to potentially beneficial drugs. Patients and their caregivers have expressed support for these programmes and see patient input as critical to
successful implementation. However, they have yet to be systematically involved in
their design.
Objective: The aim of this study was to co-design with patients and caregivers a tool
for the development of managed access programmes.
Methods: Building upon established relationships with the Canadian Organization
for Rare Disorders, the project team collaborated with patients and caregivers using
the principles of participatory action research. Data were collected at two workshops and analysed using a thematic network approach.
Results: Patients and caregivers co-designed a checklist comprised of six aspects of
an ideal MAP relating to accountability (programme goals); governance (MAP-specific
committee oversight, patient input, international collaboration); and evidence collection (outcome measures and continuation criteria, on-going monitoring and registries). They recognized that health-care resources are finite and considered disease
or drug eligibility criteria for deciding when to use a MAP (eg drugs treating diseases
for which there are no other legitimate alternatives).
Conclusions: A patient and caregiver-designed checklist was created, which emphasized patient involvement and transparency. Further research is needed to examine
the feasibility of this checklist and roles for other stakeholders.
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1 | I NTRO D U C TI O N

such as MAPs, to improve coverage for orphan and ultra-o rphan
drugs.13

Reimbursement decisions on orphan drugs (ie medicines for treating

Two workshops were held using the methods described below.

rare diseases affecting less than 5 in 10 000 people in the European
Union1) carry significant uncertainty. 2,3 Uncertainty typically arises
from a lack of high-quality information on (i) clinical benefit, (ii) value

3.1 | Study population

for money, (iii) potential adoption/diffusion and (iv) affordability.4,5

All patients and caregivers at two CORD Regional Forums were in-

The natural histories of many rare diseases, which tend to be life-

vited to participate in the workshops, which were part of the main

threatening or severely debilitating, remain poorly understood, and

Forum programme (ie no other sessions were scheduled at the same

high-quality randomized clinical trials are often difficult to conduct

time). The Forums focused on strategies for sustainable access to

because of small patient populations and limited validated outcome

therapies and explored personalized approaches to drug access.

measures.5,6

Presentations were made on assessing therapies for real-world use,

As uncertainty increases, so does the risk of making a “wrong

strategies for responsible use and different pathways for access,

decision.” Patients may be harmed and resources may be wasted

including MAPs. Prior to the Forums, participants had participated

when a treatment provided turns out to be ineffective or unsafe or

in two CORD conferences focused on improving access to thera-

when a treatment not provided turns out to be effective.4 Therefore,

pies for rare diseases and efforts to accomplish this in other coun-

to manage risk while enabling access to potentially beneficial drugs,

tries. They also included presentations on the challenges faced by

7-9

innovative ways of introducing these drugs have been developed,

decision-makers in Canada and discussions around the feasibility of

one of which may be referred to as managed access programmes

applying international experience to the Canadian context. CORD

(MAPs).4 MAPs provide patients with a drug while information

travel grants were provided to patients and families for the confer-

needed to address uncertainties is collected to inform a definitive

ences and Forums, minimizing financial barriers to attendance.

coverage decision. As an outcome-based arrangement, they resemble complex patient access schemes offered through NHS England.10
In Canada, patients, caregivers and patient organizations have ex-

3.2 | Data collection

pressed support for MAPs. Further, they perceive their input to be

Workshops built upon findings from research previously undertaken

critical to successful implementation, should such a policy option be

in collaboration with CORD (deliberative discussions with multiple

adopted. However, they have yet to be systematically involved in

stakeholders and then patients and caregivers, followed by webi-

their design.4,11

nars and priority-setting exercises with patients and families) (see
Figure S1 in Appendix A for the diagram of research progression).

2 | O B J EC TI V E

Questions focused on the 4 main types of uncertainty that decision-
makers face (listed in the Introduction) and sought to elicit information from participants on additional sources of uncertainty and

The aim of this study was to co-design with patients and caregivers a

aspects of MAPs important to them (see Table S1 in Appendix A for

tool for the development of managed access programmes.

the list of questions). Two experienced researchers facilitated both
workshops, which began with a presentation on MAPs and examples

3 | M E TH O DS

of their use. Both workshops were audio-recorded and transcribed.
No training was provided prior to the workshop, but all of the participants had attended the Forum and CORD conferences.

A participatory action research (PAR) approach was used. PAR
requires the active involvement of researchers and participants
in co-
c onstructing knowledge; promoting self- and critical

3.3 | Data analysis and interpretation

awareness (which leads to individual, collective and/or social

Transcripts were analysed using a thematic network approach,14 a

change); and building alliances for effective planning, imple-

tool for organizing the different levels of themes that emerge in a

mentation and dissemination of the research.12 In Canada, the

thematic analysis of qualitative data. Transcripts were first coded in-

Canadian Organization for Rare Disorders (CORD) represents

ductively using open coding methods.15 Codes were then clustered

the rare diseases community. It is comprised of more than 80

into “basic themes,” describing the premise of the coded data (eg

patient organizations and is recognized as the national voice

no legitimate drug alternatives).14 Basic themes focusing on similar

of this community, advocating for appropriate access to care.

issues were further grouped into “organizing themes” (eg drug pri-

In this study, we built on established relationships between

orities for MAPs).14 Finally, organizing themes were grouped into

CORD and members of the study team. At the same time, re-

“global themes,” capturing what they meant as a whole (eg best prac-

cent research from our group had demonstrated that there

tices for an ideal managed access programme).14 Constant compara-

was strong interest in the CORD community in a possible role

tive analysis was used to organize codes into themes,15 which were

for patients and families in developing innovative approaches,

subsequently mapped onto an uncertainties matrix, reflecting their

|
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link to a specific type of uncertainty. Finally, by considering how the

can’t complain!” – Caregiver 1, W1 or C1, W1), and saw themselves

themes could be operationalized in the implementation of a MAP, an

as experts in the “lived” experience. At the same time, they de-

“ideal” MAP checklist was created similar to commonly used critical

scribed challenges in this role, which related to the physician–pa-

appraisal tools.

tient relationship. Patients and caregivers often face pushback from

The checklist was reviewed by workshop participants, minimiz-

physicians who are “not open… [And] don’t always listen” (P5, W2) to

ing opportunities for bias in the interpretation of data. It was then

information patients/caregivers have gathered through their own

presented to a broader group of stakeholders who comprise mem-

research and experiences.

bers of the research and advisory teams of Promoting Rare-Disease

In general, patient organizations were viewed as trusted repre-

Innovation through Sustainable Mechanisms (PRISM; a Canadian re-

sentatives of and important information conduits for the disease

search network through which this project was funded) for further

community. As such, they are well positioned to identify and inform

feedback. These teams include clinicians, regulators, provincial drug

patients about opportunities to be involved in the life cycle (eg to

plan decision-makers and industry representatives. Based on com-

provide input into coverage decision making). When asked whether

ments received, a final version of the checklist was prepared.

there is a role for patient organizations in educating and managing
expectations of patients and caregivers around new therapies for

4 | R E S U LT S

which there may be limited clinical evidence, patients and caregivers responded “absolutely.” They also felt that those who formally or
informally contribute to decision making within the life cycle should

All patients and caregivers who attended the Regional Forum par-

share their knowledge and insights with the rest of the disease

ticipated in the workshop. They represented a range of disease

community.

types (eg cancer, non-cancerous tumour disorders, blood disorders,

With respect to the role of physicians, patients and caregivers

metabolic disorders, connective tissue disease, endocrine disorders,

felt that physicians should be responsible for ensuring their patients

lung disorders and epileptic encephalopathies) and differing levels

are aware of all treatment options, regardless of the cost. Several

of experience within their rare disease communities. Nine patients

expressed frustrations with physicians who “didn’t read the literature”

and three caregivers (10 females; 2 males) participated in the first

(P2, W2) and struggled to effectively provide care due to unfamiliar-

workshop, and five patients and three caregivers (7 females; 1 male)

ity with the rare disease.

participated in the second.
Through the workshops, four global themes reflecting “notions”
were identified. A notion is an individual’s impression of something
known, experienced or imagined16 The notions related to patients’

4.1.2 | Research on rare diseases and orphan drugs
is challenging

and caregivers’ experiences living with a rare disease and access-

Patients and caregivers reiterated the challenges involved in con-

ing appropriate therapies (eg orphan drugs). Collectively these ap-

ducting research on rare diseases and orphan drugs, the most sig-

peared to guide their views on what they considered a MAP that

nificant of which remains the poorly understood natural histories of

they felt would provide the necessary, but missing information on

rare diseases (“Well finally, at least we know I’m not the only one…” –

a new therapy. In addition to these notions, patients and caregivers

P5, W2) and its impact on the discovery of effective therapies. They

also identified specific aspects of an ideal MAP. Overarching the four

emphasized the importance of on-going collection of natural history

notions and the aspects of an ideal MAP was “sentiments,” capturing

and clinical outcomes data. They recognized that while registries

why patients valued MAPs and wanted to be involved in their design.

may play a role, they require significant resources to implement and

Further details on each notion, including examples from the tran-

maintain. “Many drugs can’t support that type of registry” and there are

scripts, can be found in Appendix A (Tables S2 and S3).

“the physicians as well…they don’t have time to fill out the paper work”
(P3, W2) for on-going data collection.

4.1 | The four notions

Patients and caregivers also identified challenges involved in
conducting clinical trials on orphan drugs in Canada. In their view,

The four notions are organized below in order of relevant stage in

trials are “not likely to be happening in Canada” (P4, W2), which is a

the life cycle of an orphan drug. Refer to Appendix A to see the the-

concern, as they represent an important means of obtaining early

matic networks behind each notion (Figures S2-S5) and for further

access to new therapies. Regardless of location, trials are limited by

details on the life cycle (Figure S6).

small patient sample sizes (“we didn’t have 99 patients that were going
to enroll”— C2, W2) and a lack of validated outcome measures.

4.1.1 | All stakeholders have roles and
responsibilities in the orphan drug life cycle
Patients and caregivers believed that all stakeholders “[have] a role

4.1.3 | Challenges around coverage decision-making
processes affect access to orphan drugs

and… a responsibility” (Patient 5, Workshop 1 or P5, W1) within the

Patients and caregivers discussed challenges in Canadian cover-

orphan drug life cycle (“I’m sorry, it’s like if you don’t go to vote, you

age decision-m aking processes that affect their ability to access
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4.2.1 | Accountability aspects

the clinical benefit of orphan drugs when one is “not quite sure

Programme goals

how it’s going to be used and what the outcomes will be…” (P1, W2).

While patients and caregivers viewed MAPs as enabling earlier ac-

However, they questioned why such processes do not routinely

cess to potentially effective therapies, they wanted to ensure that

involve specialist physicians “who know something about the dis-

this option is used appropriately or “for the right purpose” (C1, W2)—it

ease and the drug” (C1, W2). They also acknowledged the high

must be able to address research questions aimed at determining

cost of orphan drugs as an added challenge for decision-m akers,

the right dose of the right drug for the right patient. Individualized

as well as desperate demands from patients and families for ac-

treatment protocols, which involve “trying [the drug] on each individ-

cess to treatments with “no data to support [them] whatsoever…”

ual patient and seeing if it’s working for them or not” (C3, W2), may be

(P4, W1). These demands are often exacerbated by “inequality [in

required.

access] across Canada” (P7, W1), which they blamed on the lack of

Transparency in all aspects of the MAP was emphasized. This

a national health-c are system. They believed that provincial con-

includes opportunities for patient and caregiver input; as many felt

trol of health-c are budgets has hindered the implementation of

that other stakeholders do not effectively communicate, their re-

nation-w ide programmes, like the pan-C anadian Pharmaceutical

quests for input and so the patients “don’t know when these [oppor-

Alliance (pCPA; established to conduct joint drug plan negotia-

tunities] happen.” It was felt that transparent MAPs would improve

tions for brand drugs in Canada), which could directly affect ac-

patients’ acceptance of treatment decisions by helping them “under[-

cess to orphan drugs.

stand] the process a little more and [take] the sting out of why [they]

There is also a lack of transparency in drug coverage decision

can’t get medication” (P4, W1).

making. One participant wondered: “Why don’t they have accountability? Why is there no transparency there?” (P6, W1). Patients and
caregivers felt that they were purposefully kept in the dark by those
involved who “don’t want [patients/caregivers] to know” (P1, W1).

4.2.2 | Governance aspects
MAP-specific Committee

Finally, patients and families discussed how Canada represents

Patients and caregivers indicated that MAPs should be overseen

only a small share of the global drug market and is “not a friendly

by a MAP-s pecific committee with “a stipulation that there’s pa-

place for [pharmaceutical companies] to come to” (P8, W1). As a result,

tient representation” (P9, W1) from three patient members who:

there is a need for the government to introduce policy mechanisms

1) meet a minimum level of experience within the health-c are

for bringing new drugs into Canada that provide some security for

system, 2) have a meaningful role on the committee and 3) are

companies “around how long they have to recoup that money” (P8, W1).

accountable back to the organization they represent to avoid
bias and enhance knowledge translation. To this end, they saw

4.1.4 | All patients are unique
Patients and caregivers explained that no single patient can repre-

a role for patient organizations in selecting patient representatives who “understand all [their] needs… [to] go on [their] behalf”
(P3, W1).

sent the views of the entire disease group because all patients are

They also agreed that committees should include a physician

“unique” and do “not [have] just one experience” (P1, W1) “You can’t do…

who specializes in the specific rare disease—”somebody in the med-

one size fits all [with orphan drugs]” (P5, W1). Further, rare diseases

ical field who understands [the specific disease]” (P4, W1) and the

are often heterogeneous, with symptoms, severity and response to

patient community should select that physician. Finally, there was

treatment varying across patients who share a diagnosis (“…we’re not

a widely held view that committee meetings should be “open to

having the same bodies. We don’t have the same ways [of] metabolizing

anybody” (P7, W1) so that all patients/caregivers have the oppor-

[drugs]” (P3, W2)). “You’re dealing with all ages, you’re dealing with dif-

tunity to provide input into the programme. This is discussed in

ferent responses to treatment, different lifestyle… at least in our area I

detail below.

would feel very bad as a patient representative to be the only one saying
what I think are the right outcomes” (P1, W2).

Individual patient input
The importance of providing opportunities for individual pa-

4.2 | Aspects of an ideal MAP

tient and caregiver input in the development of a MAP was
stressed (“the patient, in whatever format, deserves a voice” (P2,

Additionally, patients’ and caregivers’ described the components that

W1)). Further, such input must be collected through a process

a MAP should contain. Six aspects of an ideal MAP were identified. In

that is quick, efficient and accessible (“thinking about the peo-

considering how to operationalize these components, a checklist was

ple who are at home with their disease and can’t get to meetings,

developed, which organized the aspects into three categories relat-

but want to have a voice, if they have a computer and a family

ing to accountability, governance and evidence collection (Table 1).

member they can sit beside them and put their answers in it”—

An annotated version of this checklist can be found in Appendix B,

P3, W1). Several approaches to collecting feedback were dis-

which maps the notions onto the checklist components (Table B1).

cussed, including online surveys, written documents, videos

|
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Checklist for the characteristics of an Ideal MAP

Accountability
Programme Goals
Is the MAP appropriate for the question at hand?

□ Yes

□ No

Will the patients receive earlier access to the drug?

□ Yes

□ No

Will the programme collect the evidence needed to find the right drug for the right patient?

□ Yes

□ No

Will all of the processes within the programme (eg decision making) be transparent to ensure greater buy-in?

□ Yes

□ No

Will there be a programme-specific committee established to guide the MAP?

□ Yes

□ No

Will there be 3 patient members on the committee?

□ Yes

□ No

Meet a minimum level of experience with the health-c are system

□ Yes

□ No

Have a meaningful role on the committee?

□ Yes

□ No

Are accountable back to the disease community that they represent?

□ Yes

□ No

Will patient organizations select the patient members?

□ Yes

□ No

Will there be a physician committee member?

□ Yes

□ No

Will they be an expert in the rare disease?

□ Yes

□ No

Will patient organizations select the physician member?

□ Yes

□ No

Will the committee meetings be open to all patients and caregivers who wish to attend?

□ Yes

□ No

Will individual input from a broad range of patients be collected to develop the MAP?

□ Yes

□ No

Will the process be quick and efficient?

□ Yes

□ No

Will there be a variety of ways for patients to provide input?

□ Yes

□ No

Will the input processes be transparent and patients well informed of the opportunity?

□ Yes

□ No

Will there be collaboration with other countries to learn from their experiences with MAPs?

□ Yes

□ No

Will there be collaboration with other countries to conduct trials (if necessary)?

□ Yes

□ No

Will there be collaboration with experts in other countries to educate Canadian physicians on the rare disease?

□ Yes

□ No

Will there be on-going monitoring with an engaged physician and good documentation (eg through EMRs)?

□ Yes

□ No

Will the following information be collected:

□ Yes

□ No

Governance
Programme-Specific Committee

Will the patient members meet the follow criteria:

Individual Patient Input

International Collaboration

Evidence Collection
On-going Monitoring and Registries

Natural history data?

□ Yes

□ No

Qualitative data?

□ Yes

□ No

Clinical outcomes?

□ Yes

□ No

Will the outcome measures used be meaningful to patients and adequately capture their experiences?

□ Yes

□ No

Will patients provide input on meaningful outcome measures?

□ Yes

□ No

Will decisions to continue/discontinue therapy be made between physicians and patients without the use of set
continuation criteria?

□ Yes

□ No

Will there be follow-through on the results of the MAP?

□ Yes

□ No

Outcome Measures and Continuation Criteria

or face-to-face interviews with the committee. While most

International collaboration

agreed that online surveys are an effective and efficient way

Given the nature of rare diseases, patients and caregivers proposed

of gathering input from as many patients as possible, some

collaborating with other countries on certain MAPs, using the ex-

felt there should still be an opportunity for an individual to

periences of patients across multiple countries. They provided the

present to a committee (ie “the choice of doing it in person”—P6,

example of patients who have participated in clinical trials based out

W1).

of the United States and wondered if for MAPs there could be “a

978
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parallel sort of thing where the [Canadian] physician enters [data] into…
[a] US database” (P4, W2). Also, there may be opportunities to learn

4.3 | The role of MAPs

from other countries that use MAPs and potentially “adopt one of

In addition to the 4 notions described above, 3 overarching “senti-

[their] systems” (P1, W1).

ments” emerged. These captured why patients and caregivers felt
MAPs were a reasonable solution for addressing the uncertainties
that coverage decision-makers face. While the workshops were not

4.2.3 | Evidence collection aspects

intended to gather information on why patients and caregivers sup-

Outcome measures and continuation criteria

ported the use of MAPs, these sentiments were embedded through-

Patients and caregivers believed they should have an opportunity to

out their discussions around what MAPs should look like.

provide input on the outcome measures selected and used as continu-

First, trust in other stakeholders is often lacking. Patients and

ation criteria to ensure they are meaningful. They felt that patients

caregivers questioned the meaningfulness of many outcome mea-

should be asked, “What do you think? What else can you tell us?” (C1,

sures used in decision-making processes that they feel are opaque

W2). With respect to continuation criteria, where these could not be

(“Maybe they don’t want us to know” – P4, W1). Some did not trust

determined a priori (eg for poorly understood, ultra-rare, heterogene-

their physicians to know which therapies were most appropriate.

ous diseases), participants felt that decisions around continuation on

One patient described receiving a prescription that she later “found

therapy should be made through a conversation between patients and

out… [they] should have never… had” (P7, W2). Also, at times, they felt

their physicians (eg “try and up the dose”—P4, W2).

that their physician chose not to inform them of all their treatment

At the same time, the need to “act on the answer” (P1, W2) pro-

options because of the costs. “Physicians [make] treatment decisions

vided through a MAP was stressed by patients and caregivers.

based on the cost of the drug” (P2, W1), not on its potential effective-

Where the treatment proves ineffective based on previously agreed

ness, assuming “[the patient] can’t afford it.”

outcomes, participants indicated it should be discontinued, with

The second “sentiment” was desperation. Patients and families
described feeling desperate to find a treatment for their disease,

decision-makers enforcing follow-through.

particularly when no alternatives exist. They become willing to try
“..so you do have to set schemes up in such a way (1) in

almost anything and accept risk thresholds that are much higher

hope of getting an answer and (2) that you’re going to act

than those accepted by their health-care providers. They “[are] emo-

on the results in a reasonable kind of way.” 

tional, [and they] want to get better” (P1, W1) so if they are offered

(C2, W2)

access to a drug in a trial or a MAP “[they’ll] sign anything” (P9, W1)
to participate.

On-going monitoring and registries

The third “sentiment” that emerged was hope. Patients and care-

Patients and caregivers felt that MAPs must have “a documentation

givers were steadfast in their belief that access to orphan drugs can

process in place” (P2, W2) to support on-going monitoring with an en-

be improved. One caregiver said: “I’m not giving up for anything. And

gaged physician and data collection should begin before treatment

if my son doesn’t make it, I’ll also be fighting for the other ones” (C2,

is started (eg natural history registries) to identify “the stages of that

W1). This theme was apparent in both patients’ and caregivers’ en-

patient journey… [and] the progressions” (C1, W2) of the disease. Once

thusiasm around the workshop dedicated to the design of an ideal

treatment has begun, registries should collect qualitative and quan-

MAP and in their discussions about uncertainty and the difficulty it

titative data related to the impact of the drug.

creates for decision-makers. They recognized that these uncertainties are an issue, but felt there are ways they could be involved to

4.2.4 | Disease/drug priorities

help reduce them (“Let’s get [it] done…”—C2, W1), such as identifying
meaningful outcome measures (“…it’s fairly easy to ask the [patients]

Patients and caregivers recognized that health-care resources are finite

what they would see as success”—P1, W2) and contributing to decision-

and that it is infeasible to have a MAP for every drug. As such, they

making committees.

also considered possible disease or drug eligibility criteria for deciding
when to use a MAP. They included drugs that treat “life-threatening or
chronically debilitating conditions” (P2, W1) and those for which there are

5 | D I S CU S S I O N

no other legitimate alternatives (ie when an alternative exists but is not
an option for all patients, eg, due to intolerance). Drugs that are innova-

The work described in this study contributes to the growing body

tive (ie offer a new mechanism of action) or high cost were also seen as

of literature supporting the inclusion of patients in the assessment

priorities. When asked whether disease prevalence alone is a sufficient

of new health technologies to inform reimbursement decisions. To

criterion to make a drug a priority for a MAP, patients and caregivers

date, much of the attention has been focused on the development of

both responded “no.” While there was broad agreement from patients

generic guidance documents for patient involvement in HTA, such as

and caregivers on these criteria, some wondered “why we…are even

those developed by the European Patients Academy (EUPATI).17,18

thinking about excluding [drugs]” (P4, W1), arguing that the use of MAPs

Several of the items on the MAP checklist are consistent with these

for all drugs may make the health-care system more efficient.

documents. For example, the EUPATI calls for the nomination
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of patient and clinical experts by patient organizations to serve

Canada. However, CORD is comprised of over 80 different rare

on HTA committees. They are also consistent with The European

disease patient organizations and covers travel expenses for pa-

Organization for Rare Diseases’ Charter that provides principles for

tients and caregivers to attend their events, reducing the likeli-

collaboration between sponsors and patient organizations.19

hood of bias.

The MAPs checklist is an example of a tool co-d esigned by patients and caregivers to not only improve access to high-cost drugs
for rare diseases, but also generate the kind of evidence needed

6 | CO N C LU S I O N

to inform appropriate reimbursement (ie right drug for the right
patient at the right time). To our knowledge, no other such tool

The MAP checklist co-designed by patients and caregivers offers a

exists. However, some jurisdictions, such as England and Wales,

tool for informing the development and evaluation of such policy

have already implemented MAP-like schemes [ie patient access

options, which aim to improve access to drugs where there is a high

schemes (PAS)]. While PAS proposals from pharmaceutical com-

degree of uncertainty in the available evidence. Future research is

panies are not co-d esigned by patients or caregivers, their input

needed to examine the feasibility of this checklist and roles for other

is sought during the review process managed by the National

stakeholders.

Institute for Health and Clinical Excellence (NICE).10 Those that
take the form of a “complex scheme,” where pricing and reimbursement is outcome-b ased, share many of the elements presented in the MAPs checklist.
Additionally, a checklist for evaluating access with evidence development (AED) schemes, which serve a similar purpose to MAPs,

AC K N OW L E D G E M E N T S
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has been published. 20 Specifically, AEDs provide interim coverage to
patients through participation in a study designed to generate evidence needed to make a definitive coverage decision. The elements
are broadly similar to those of the MAPs checklist.
While much of this work focussed on what an ideal MAP
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should look like, general discussions around the current context
of orphan drug access, the challenges that patients and caregivers face and, ultimately, why MAPs was viewed as an appropriate solution also took place. The three sentiments identified from
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these discussions (trust, hope and desperation) have been documented in published literature. One study found that patients with
lower levels of trust in their physician were more likely to want an
autonomous role in treatment decision making. 21 Another study
which involved a qualitative analysis of cancer patients’ conversations demonstrated that hope often served as a justification for
action. 22 Finally, a recent ethics paper argued that it is a combination of desperation and hope that motivates patients with untreatable diseases to drastic measures to find potentially effective
therapies. 23
It was also recognized that MAPs will not address all of the issues that patients and families face with respect to managing rare
diseases (eg the exclusion of patients and specialists with relevant
expertise from committees reviewing submissions for drug coverage or disparities in access to coverage across Canadian provinces and territories). Studies on the reasonableness of patients
and their willingness to accept limits have been documented in
other studies. 24,25

5.1 | Limitations
Both workshops were held at national events hosted by CORD, and
it is possible that the individuals who chose to participate in these
events were not representative of the rare disease population in
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